Clinical Trial

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-12-11; most recent amendment 2026-06-04.
Status change: Suspended → Recruiting 2026-04-14
Status change: Not Yet Recruiting → Suspended 2026-02-25
Trial Details
NCT Number NCT07283705
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Bristol-Myers Squibb
Conditions Phase 2 Study, BMS-986504, MTAP-deleted Pancreatic Cancer
Enrollment 60 participants
Start Date 2026-05-18
Primary Completion 2029-10-01 (estimated)
Study Completion 2031-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-08